In 26/40 patients (65%), G-CSF was initiated when neutropenia symptoms were detected but in the remaining 14/40 (35%), G-CSF was previously prescribed to prevent febrile neutropenia after a routine chemotherapy administration. This evidence concerns the gene CSF3 and Decreased total neutrophil count.